Brain Imaging for Post-Heart Attack Inflammation

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: University of Alabama at Birmingham

No Placebo Group

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of the study is to see if positron emission tomography and magnetic resonance imaging (PET/MRI) with an investigational drug called \[18F\]DPA-714 will show inflammation in the brain after a heart attack. This study may help physicians and researchers better understand the role of brain inflammation in heart disease and develop new treatments to protect the brain.

Research Team

Eligibility Criteria

This trial is for adults over 21 who've had a recent heart attack treated with PCI or are undergoing elective PCI. They must speak English, have at least an 8th-grade education, and be genetically predisposed to brain inflammation after a heart attack. People can't join if they're pregnant, breastfeeding, have serious health issues that could affect participation, history of severe head injury, major depression or dementia.

Inclusion Criteria

I am admitted to UAB Hospital for a severe heart attack and treated with PCI, or I am undergoing elective PCI.

I am 21 years old or older.

I speak English and have completed at least 8th grade.

Exclusion Criteria

I have had heart bypass surgery in the past.

You have had a serious head injury that caused you to lose consciousness for more than 30 minutes or have a seizure.

I have had a heart attack before.

Treatment Details

Interventions

• [18F]DPA-714 (Radiopharmaceutical)

Trial Overview The study tests whether PET/MRI scans using the investigational drug [18F]DPA-714 can detect brain inflammation following a heart attack. This research aims to understand how heart disease affects the brain and may lead to new protective treatments.

Participant Groups

Group I: undergoing elective percutaneous coronary intervention Experimental Treatment 1 Intervention

Group II: Recent Myocardial Infarction Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials

1,677

Recruited

2,458,000+

Kierstin Kennedy

University of Alabama at Birmingham

Chief Medical Officer since 2022

MD

S. Dawn Bulgarella

University of Alabama at Birmingham

Chief Executive Officer since 2023

BSc in Commerce and Business Administration from the University of Alabama, MS in Health Administration from the University of Alabama at Birmingham